Mobile App

Google Play Apple Store
Current and Emerging Perspectives in Chronic Immune Thrombocytopenia - Updated 8/18/2022
AMA/ANCC Activity
Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to bruising and bleeding. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. Since 2008, the approval of thrombopoietin-receptor agonists (TPO-RAs) including a second-generation oral TPO-RA and a spleen tyrosine kinase (Syk) inhibitor, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment. This landscape will be further transformed with a sizable clinical pipeline including inhibitors of CD20, CD40, neonatal Fc receptor (FcRn), bruton’s tyrosine kinase (BTK), and Syk signaling.

This slide kit is designed to keep busy clinicians abreast of the emerging evidence for available treatments and the novel therapy pipeline, to optimize the treatment and care for patients with ITP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.
Review this activity and claim AMA or ANCC credit/contact hour(s) after completion of the post-test / evaluation.

Hanny Al-Samkari, MD Hanny Al-Samkari, MD
Hematologist and Clinical Investigator
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Supported by an independent educational grant from Dova Pharmaceuticals, A Sobi Company

Launch Date: August 30, 2021
Release Date: August 30, 2021
Expiration Date: December 31, 2022
December 31, 2022
Mini Module


Change Settings